SAN DIEGO, Aug.  06, 2026  (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., (&#34;BlossomHill Therapeutics&#34;), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to

BLSM

BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

BlossomHill Therapeutics launches upsized IPO for BLSM with strong syndicate

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, Aug.  06, 2026  (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., (&amp;#34;BlossomHill Therapeutics&amp;#34;), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>BlossomHill Therapeutics priced an upsized IPO at $16 per share for 9.375 million shares, aiming for about $150 million in gross proceeds. The offering includes a 30-day option to purchase up to 1,406,250 additional shares. BLSM will begin trading on Nasdaq on August 7, 2026, with an August 10 close, funding lead oncology programs BH-30643, BH-30236 and BH-501284.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>BlossomHill pricing upsized IPO of 9.375M shares at $16.</li><li>Gross proceeds expected around $150 million; 30-day overallotment option granted.</li><li>Trading on Nasdaq Global Select as BLSM starts August 7, 2026; close on August 10.</li><li>Lead managers JPMorgan, Leerink, Guggenheim; LifeSci Capital and H.C. Wainwright also involved.</li><li>BlossomHill’s lead programs BH-30643, BH-30236, and BH-501284 highlighted.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>BlossomHill Therapeutics (BLSM)</strong>: IPO pricing and Nasdaq listing; proceeds to fund lead oncology programs BH-30643, BH-30236, BH-501284.</li><li><strong>J.P. Morgan (JPM)</strong>: Lead book-running manager; strong distribution capability may influence initial demand.</li><li><strong>Leerink Partners (N/A)</strong>: Joint book-running manager; biotech IPO track record supports pricing and book-building.</li><li><strong>Guggenheim Securities (N/A)</strong>: Joint book-running manager; broad investor reach aids price discovery.</li><li><strong>LifeSci Capital (N/A)</strong>: Joint book-running manager; biotech-focused, contributes to order flow.</li><li><strong>H.C. Wainwright &amp; Co. (N/A)</strong>: Joint book-running manager; experienced in oncology IPOs, supports demand.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article covers an IPO pricing and listing event, a key funding and capitalization milestone for BlossomHill that can influence short-term equity dynamics and investor sentiment around BLSM.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Upsized share count implies incremental dilution for existing holders, affecting near-term value.</li><li>First-day trading demand will set initial price direction and volatility for BLSM.</li><li>Strong underwriting syndicate provides price discovery support but biotech IPOs remain volatile.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Shares offered: 9,375,000.</li><li>Price to public: $16.00.</li><li>Estimated gross proceeds: $150.0 million.</li><li>Overallotment: up to 1,406,250 shares.</li><li>Trading start date: August 7, 2026; close date: August 10, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term neutral to cautiously positive if first-day demand supports BLSM above $16; monitor post-IPO price action over 1–3 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, Aug.  06, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=9t3FZYrs686YhNyyO7FRssEIlrteM4tpr6WJkciDTTgVhdreuddf0lymZp--6qlO0kJe-9NZHQNoFxhgoUoYQK8yUiWxX4jNwuhYkeb95Tld_V-4WSUUyWqkFx-2GjQN" rel="nofollow" target="_blank"><u>BlossomHill Therapeutics, Inc.</u></a>, ("BlossomHill Therapeutics"), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines for the treatment of cancer, today announced the pricing of its upsized initial public offering of 9,375,000 shares of common stock at a price to the public of $16.00 per share. The gross proceeds to BlossomHill Therapeutics from the offering, before deducting underwriting discounts and commissions and offering expenses payable by BlossomHill Therapeutics, are expected to be $150.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. In addition, BlossomHill Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by BlossomHill Therapeutics.</p>  <p>The shares are expected to begin trading on The Nasdaq Global Select Market on August 7, 2026, under the ticker symbol "BLSM." The offering is expected to close on August 10, 2026, subject to the satisfaction of customary closing conditions.</p>  <p>J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as lead book-running managers for the offering. LifeSci Capital and H.C. Wainwright &amp; Co. are acting as joint book-running managers for the offering.</p>  <p>Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on August 6, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities. When available, copies of the final prospectus relating to the initial public offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105 or by email at syndicate@leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at <a href="https://www.globenewswire.com/Tracker?data=vy-dDV7IbbIMW05CVkcWf1MwgrsQQ_37lxPaNmpoaLAFEL1XkvMi_mzfzGmTw-3U5Ih5nrCHvzRkFzgg99EaLQTlY6j1kGG-mw3UaXud9s2xh9_VIO92aCty2Jpqa_t0aMQ5gluJ2L3Hv9j29Uhdh6i1aCK4jCPbe2D6o7TYAjoLl6UFyfzA_SKY5ZaDjZoA" rel="nofollow" target="_blank">GSEquityProspectusDelivery@guggenheimpartners.com</a>.</p>  <p>This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.</p>  <p><strong>About BlossomHill Therapeutics </strong><br></br>BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical programs include BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) with an initial development focus in the C797S resistance population after 3rd generation EGFR TKI treatment, and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being developed for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS) and BH-501284, our preclinical, non-covalent, selective, pan-KRAS Switch II inhibitor for potential future development in diverse KRAS-mutant tumors. BlossomHill Therapeutics is headquartered in San Diego, California.</p>  <p><strong>Company Contact: </strong><br></br>Michael Moore, BlossomHill Therapeutics<br></br>michael.moore@bhtherapeutics.com</p>  <p><strong>Media: </strong><br></br>Ashlea Kosikowski, 1AB <br></br>ashlea@1abmedia.com</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwNTgwMSM3NzY0NjI4IzIyMDc1NTM="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YWY4NzJkNjAtZTVmNS00MmFkLTk5NzctNDczODM5ZDViOTlmLTEyMTkxMDYtMjAyNi0wOC0wNy1lbg==/tiny/BlossomHill-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/02f747e9-636d-467e-81f8-d942e9421158"><img src="https://ml.globenewswire.com/media/02f747e9-636d-467e-81f8-d942e9421158/small/blossomhill-vertical-fullcolor-cmyk1-jpg.jpg" border="0" width="150" height="74" alt="Primary Logo"></img></a></p>

BlossomHill Therapeutics priced an upsized IPO at $16 per share for 9.375 million shares, aiming for about $150 million in gross proceeds. The offering includes a 30-day option to purchase up to 1,406,250 additional shares. BLSM will begin trading on Nasdaq on August 7, 2026, with an August 10 close, funding lead oncology programs BH-30643, BH-30236 and BH-501284.

News insight

BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

AI summary

Sentiment rationale

Key facts

Corporate Developments